AnaptysBio, Inc. (NASDAQ: ANAB) reported Q3 EPS of ($1.14), $0.56 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $30.02 million versus the consensus estimate of $6.92 million.

For earnings history and earnings-related data on AnaptysBio, Inc. (ANAB) click here.